CytomX Therapeutics, Inc. (CTMX)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
2.41 USD
+0.18
(8.072%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:47 a.m. EDT
The investment case for CytomX is currently defined by a stark disconnect between optimistic analyst targets and a deteriorating reality. While analysts project a mean price of $12.25, the company is fundamentally broken: revenue has collapsed by 92% year-over-year, and the business is burning through cash at a rapid pace with no visible path to profitability. The balance sheet, while currently liquid, cannot sustain this burn without dilution or a successful catalyst. The most critical signal is the overwhelming options activity. Traders are flooding the market with put options, creating a heavy hedge against a crash. This speculative positioning aligns with the grim fundamentals: the stock is trading at a premium to sales despite losing nearly all its revenue, and the recent price action shows a steady bleed lower, testing the 52-week lows. The statistical forecast model offers no help, showing zero directional bias due to the noise inherent in such a volatile, distressed biotech name. In short, the market is pricing in a failure scenario. Unless there is an immediate, miraculous clinical breakthrough or a major partnership announcement, the trajectory points toward further downside as the cash pile depletes and the stock gets re-rated to reflect its lack of commercial traction. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.168919 |
| AutoARIMA | 0.168920 |
| MSTL | 0.169334 |
| AutoTheta | 0.189818 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 45.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.198 |
| Excess Kurtosis | -1.29 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.888 |
| Revenue per Share | 0.1 |
| Market Cap | 525,137,280 |
| Forward P/E | -5.13 |
| Beta | 2.20 |
| Website | https://www.cytomx.com |
As of Oct. 10, 2026, 4:47 a.m. EDT: Speculators are aggressively positioning for downside protection with massive volume in out-of-the-money puts (over 4,200 contracts) compared to negligible call volume. This 'put wall' suggests a strong consensus expectation of a significant price drop within the next few months, likely driven by fears of further clinical trial failures or cash burn issues, despite the presence of some long-dated call buying.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24687499 |
| Address1 | 151 Oyster Point Boulevard |
| Address2 | Suite 400 |
| All Time High | 35.0 |
| All Time Low | 0.4 |
| Ask | 2.43 |
| Ask Size | 22 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 3,179,550 |
| Average Daily Volume3 Month | 3,342,559 |
| Average Volume | 3,342,559 |
| Average Volume10Days | 3,179,550 |
| Beta | 2.204 |
| Bid | 2.42 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 1.386 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.41 |
| Current Ratio | 9.361 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.435 |
| Day Low | 2.25 |
| Debt To Equity | 1.888 |
| Display Name | CytomX Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,050,000 |
| Earnings Call Timestamp Start | 1,786,050,000 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -86,211,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.326 |
| Enterprise To Revenue | 10.958 |
| Enterprise Value | 200,561,280 |
| Eps Current Year | -0.38876 |
| Eps Forward | -0.47023 |
| Eps Trailing Twelve Months | -0.51 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 351 0353 |
| Fifty Day Average | 3.0622 |
| Fifty Day Average Change | -0.6522 |
| Fifty Day Average Change Percent | -0.21298411 |
| Fifty Two Week Change Percent | -24.687498 |
| Fifty Two Week High | 8.21 |
| Fifty Two Week High Change | -5.8 |
| Fifty Two Week High Change Percent | -0.7064556 |
| Fifty Two Week Low | 2.2 |
| Fifty Two Week Low Change | 0.21000004 |
| Fifty Two Week Low Change Percent | 0.09545456 |
| Fifty Two Week Range | 2.2 - 8.21 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,444,311,000,000 |
| Float Shares | 179,664,497 |
| Forward Eps | -0.47023 |
| Forward P E | -5.1251516 |
| Free Cashflow | -75,212,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 69 |
| Fullday Change | -0.08000016 |
| Fullday Change Percent | -3.3195088 |
| Fullday Price | 2.33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 18,303,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00574 |
| Held Percent Institutions | 1.0448201 |
| Implied Shares Outstanding | 217,899,284 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California. |
| Long Name | CytomX Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 525,137,280 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_60504284 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -82,655,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 606,849,505 |
| Number Of Analyst Opinions | 8 |
| Open | 2.26 |
| Operating Cashflow | -82,408,000 |
| Operating Margins | -16.7708 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 650 515 3185 |
| Pre Market Change | -0.08000016 |
| Pre Market Change Percent | -3.3195088 |
| Pre Market Price | 2.33 |
| Pre Market Time | 1,792,144,339 |
| Previous Close | 2.23 |
| Price Eps Current Year | -6.199198 |
| Price Hint | 4 |
| Price To Book | 1.7388167 |
| Price To Sales Trailing12 Months | 28.691322 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.264 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.375 |
| Region | US |
| Regular Market Change | 0.18 |
| Regular Market Change Percent | 8.07175 |
| Regular Market Day High | 2.435 |
| Regular Market Day Low | 2.25 |
| Regular Market Day Range | 2.25 - 2.435 |
| Regular Market Open | 2.26 |
| Regular Market Previous Close | 2.23 |
| Regular Market Price | 2.41 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 2,985,207 |
| Return On Assets | -0.19584 |
| Return On Equity | -0.37752 |
| Revenue Growth | -0.924 |
| Revenue Per Share | 0.1 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 217,899,284 |
| Shares Percent Shares Out | 0.1873 |
| Shares Short | 40,813,393 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 33,512,293 |
| Short Name | CytomX Therapeutics, Inc. |
| Short Percent Of Float | 0.2125 |
| Short Ratio | 9.26 |
| Source Interval | 15 |
| State | CA |
| Symbol | CTMX |
| Target High Price | 16.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 12.25 |
| Target Median Price | 12.0 |
| Total Cash | 330,280,000 |
| Total Cash Per Share | 1.516 |
| Total Debt | 5,704,000 |
| Total Revenue | 18,303,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.51 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.97765 |
| Two Hundred Day Average Change | -1.5676498 |
| Two Hundred Day Average Change Percent | -0.39411458 |
| Type Disp | Equity |
| Volume | 2,985,207 |
| Website | https://www.cytomx.com |
| Zip | 94,080 |